Abstract
Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the most important component of systemic therapy for hormone-responsive breast cancer. Unfortunately, endocrine-resistant ER-positive disease represents up to one-quarter of all breast cancers and a number of different mechanisms have been implicated in endocrine resistance, either intrinsic, occurring de novo at the initial exposure to endocrine therapies or acquired, occurring after an initial response to therapy. In the present work a number of molecular mechanisms accounting for intrinsic and acquired resistance to hormonal therapies have been reviewed and the most promising strategies to overcome endocrine resistance have been highlighted.
Keywords: Estrogen receptor, hormone resistance, breast cancer
Current Cancer Drug Targets
Title: Overcoming Endocrine Resistance in Breast Cancer
Volume: 10 Issue: 5
Author(s): R.A. Madaio, G. Spalletta, L. Cravello, M. Ceci, L. Repetto and G. Naso
Affiliation:
Keywords: Estrogen receptor, hormone resistance, breast cancer
Abstract: Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the most important component of systemic therapy for hormone-responsive breast cancer. Unfortunately, endocrine-resistant ER-positive disease represents up to one-quarter of all breast cancers and a number of different mechanisms have been implicated in endocrine resistance, either intrinsic, occurring de novo at the initial exposure to endocrine therapies or acquired, occurring after an initial response to therapy. In the present work a number of molecular mechanisms accounting for intrinsic and acquired resistance to hormonal therapies have been reviewed and the most promising strategies to overcome endocrine resistance have been highlighted.
Export Options
About this article
Cite this article as:
Madaio R.A., Spalletta G., Cravello L., Ceci M., Repetto L. and Naso G., Overcoming Endocrine Resistance in Breast Cancer, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517226
DOI https://dx.doi.org/10.2174/156800910791517226 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets Sugar-Borate Esters – Potential Chemical Agents in Prostate Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Tamoxifen Citrate Loaded Ethosomes for Transdermal Drug Delivery System: Preparation and Characterization
Current Drug Delivery Mechanism of Action and Potential Use of Tamoxifen in the Treatment of Acute Mania
Current Psychopharmacology Antiproliferative Effects of Molecular Iodine in Cancers
Current Chemical Biology Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design Assessment of Ploy Dopamine Coated Fe<sub>3</sub>O<sub>4</sub> Nanoparticles for Melanoma (B16-F10 and A-375) Cells Detection
Anti-Cancer Agents in Medicinal Chemistry Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer
Current Cancer Drug Targets Extracts and Flavonoids of <i>Passiflora</i> Species as Promising Anti-inflammatory and Antioxidant Substances
Current Pharmaceutical Design DNA Repair Pathways and Human Metastatic Malignant Melanoma
Current Molecular Medicine Selective Gene Amplification for High-Throughput Sequencing
Recent Patents on DNA & Gene Sequences A3 Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Synthesis and Biological Activity of Novel 1-((benzofuran-2-yl)methyl)-1Htriazole Derivatives
Letters in Drug Design & Discovery CD26: A Multi-Purpose Pharmacological Target
Current Clinical Pharmacology Nanocarriers in Improved Heparin Delivery: Recent Updates
Current Pharmaceutical Design Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews